PlainRecalls
FDA Drug Moderate Class II Terminated

Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA 19454.

Reported: March 3, 2021 Initiated: February 10, 2021 #D-0271-2021

Product Description

Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA 19454.

Reason for Recall

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
50 vials
Distribution
Product was distributed nationwide in the USA and Puerto Rico.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA 19454.. Recalled by Teva Pharmaceuticals USA. Units affected: 50 vials.
Why was this product recalled?
Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 3, 2021. Severity: Moderate. Recall number: D-0271-2021.